|
1
|
Siegel RL, Kratzer TB, Giaquinto AN, Sung
H and Jemal A: Cancer statistics, 2025. CA Cancer J Clin. 75:10–45.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yao L, Hatami M, Ma W and Skutella T:
Vaccine-based immunotherapy and related preclinical models for
glioma. Trends Mol Med. 30:965–981. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tariq R, Hussain N, Bajwa MH, Aziz HF,
Shamim MS and Enam SA: Multicentric low-grade glioma: A systematic
review of a rare neuro-oncological disease. Clin Neurol Neurosurg.
251:1088212025. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weller M, Wen PY, Chang SM, Dirven L, Lim
M, Monje M and Reifenberger G: Glioma. Nat Rev Dis Primers.
10:332024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Awuah WA, Ben-Jaafar A, Roy S,
Nkrumah-Boateng PA, Tan JK, Abdul-Rahman T and Atallah O:
Predicting survival in malignant glioma using artificial
intelligence. Eur J Med Res. 30:612025. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schaff LR and Mellinghoff IK: Glioblastoma
and other primary brain malignancies in adults: A review. JAMA.
329:574–87. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kampers LFC, Metselaar DS, Vinci M,
Scirocchi F, Veldhuijzen van Zanten S, Eyrich M, Biassoni V,
Hulleman E, Karremann M, Stucker W and Van Gool SW: The complexity
of malignant glioma treatment. Cancers (Basel). 17:8792025.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Poorva P, Mast J, Cao B, Shah MV, Pollok
KE and Shen J: Killing the killers: Natural killer cell therapy
targeting glioma stem cells in high-grade glioma. Mol Ther.
33:2462–2478. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma X, Sun C, Ding X, Xu J, Zhang Y, Deng
T, Wang Y, Yang H, Ding R, Li H, et al: Mechanism analysis and
targeted therapy of IDH gene mutation in glioma. Am J Cancer Res.
15:248–270. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gong G, Jiang L, Zhou J and Su Y:
Advancements in targeted and immunotherapy strategies for glioma:
Toward precision treatment. Front Immunol. 15:15370132024.
View Article : Google Scholar
|
|
11
|
Llibre A, Kucuk S, Gope A, Certo M and
Mauro C: Lactate: A key regulator of the immune response. Immunity.
58:535–554. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Papaneophytou C: The warburg effect: Is it
always an enemy? Front Biosci (Landmark Ed). 29:4022024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gong T, Wang QD, Loughran PA, Li YH, Scott
MJ, Billiar TR, Liu YT and Fan J: Mechanism of lactic
acidemia-promoted pulmonary endothelial cells death in sepsis: Role
for CIRP-ZBP1-PANoptosis pathway. Mil Med Res. 11:712024.PubMed/NCBI
|
|
14
|
Iozzo M, Pardella E, Giannoni E and
Chiarugi P: The role of protein lactylation: A kaleidoscopic
post-translational modification in cancer. Mol Cell. 85:1263–1279.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lv M, Huang Y, Chen Y and Ding K:
Lactylation modification in cancer: Mechanisms, functions, and
therapeutic strategies. Exp Hematol Oncol. 14:322025. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen J, Huang Z, Chen Y, Tian H, Chai P,
Shen Y, Yao Y, Xu S, Ge S and Jia R: Lactate and lactylation in
cancer. Signal Transduct Target Ther. 10:382025. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao L, Qi H, Lv H, Liu W, Zhang R and
Yang A: Lactylation in health and disease: Physiological or
pathological? Theranostics. 15:1787–821. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li S, Dong L and Wang K: Current and
future perspectives of lysine lactylation in cancer. Trends Cell
Biol. 35:190–193. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang D, Tang Z, Huang H, Zhou G, Cui C,
Weng Y, Liu W, Kim S, Lee S, Perez-Neut M, et al: Metabolic
regulation of gene expression by histone lactylation. Nature.
574:575–580. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Luo Y, Zhang N, Ye J, Wang Z, Zhou X, Liu
J, Cai J, Li C and Chen L: Unveiling lactylation modification: A
new hope for cancer treatment. Biomed Pharmacother. 184:1179342025.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sui Y, Shen Z, Wang Z, Feng J and Zhou G:
Lactylation in cancer: Metabolic mechanism and therapeutic
strategies. Cell Death Discov. 11:682025. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Al-Malsi K, Xie S, Cai Y, Mohammed N, Xie
K, Lan T and Wu H: The role of lactylation in tumor growth and
cancer progression. Front Oncol. 15:15167852025. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qiu Q, Deng H, Song P, Liu Y and Zhang M:
Lactylation in glioblastoma: A novel epigenetic modifier bridging
epigenetic plasticity and metabolic reprogramming. Int J Mol Sci.
26:33682025. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lu X, Zhou Z, Qiu P and Xin T: Integrated
single-cell and bulk RNA-sequencing data reveal molecular subtypes
based on lactylation-related genes and prognosis and therapeutic
response in glioma. Heliyon. 10:e307262024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu Z, Wu H, Dai Y, Wang Z, Han H, Shen Y,
Zhang R and Wang X: A pan-cancer multi-omics analysis of
lactylation genes associated with tumor microenvironment and cancer
development. Heliyon. 10:e274652024. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Khan T, Nagarajan M, Kang I, Wu C and
Wangpaichitr M: Targeting metabolic vulnerabilities to combat drug
resistance in cancer therapy. J Pers Med. 15:502025. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Clay R, Li K and Jin L: Metabolic
signaling in the tumor microenvironment. Cancers (Basel).
17:1552025. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Barba I, Carrillo-Bosch L and Seoane J:
Targeting the warburg effect in cancer: Where do we stand? Int J
Mol Sci. 25:31422024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liao M, Yao D, Wu L, Luo C, Wang Z, Zhang
J and Liu B: Targeting the Warburg effect: A revisited perspective
from molecular mechanisms to traditional and innovative therapeutic
strategies in cancer. Acta Pharm Sin B. 14:953–1008. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang W, Xia M, Li J, Liu G, Sun Y, Chen X
and Zhong J: Warburg effect and lactylation in cancer: Mechanisms
for chemoresistance. Mol Med. 31:1462025. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Upadhyay S, Khan S and Hassan MI:
Exploring the diverse role of pyruvate kinase M2 in cancer:
Navigating beyond glycolysis and the Warburg effect. Biochim
Biophys Acta Rev Cancer. 1879:1890892024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Basheeruddin M and Qausain S:
Hypoxia-Inducible Factor 1-Alpha (HIF-1alpha): An essential
regulator in cellular metabolic control. Cureus. 16:e638522024.
|
|
33
|
Sharma D, Singh M and Rani R: Role of LDH
in tumor glycolysis: Regulation of LDHA by small molecules for
cancer therapeutics. Semin Cancer Biol. 87:184–95. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu T, Han S, Yao Y and Zhang G: Role of
human monocarboxylate transporter 1 (hMCT1) and 4 (hMCT4) in tumor
cells and the tumor microenvironment. Cancer Manag Res. 15:957–975.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Singh M, Afonso J, Sharma D, Gupta R and
Kumar V, Rani R, Baltazar F and Kumar V: Targeting monocarboxylate
transporters (MCTs) in cancer: How close are we to the clinics?
Semin Cancer Biol. 90:1–14. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang L, Li S, Yu L, Leng J and Li N:
Targeting glycolysis: Exploring a new frontier in glioblastoma
therapy. Front Immunol. 15:15223922025. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Paul S, Ghosh S and Kumar S: Tumor
glycolysis, an essential sweet tooth of tumor cells. Semin Cancer
Biol. 86:1216–1230. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sun F, Li W, Du R, Liu M, Cheng Y, Ma J
and Yan S: Impact of glycolysis enzymes and metabolites in
regulating DNA damage repair in tumorigenesis and therapy. Cell
Commun Signal. 23:442025. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kooshan Z, Cardenas-Piedra L, Clements J
and Batra J: Glycolysis, the sweet appetite of the tumor
microenvironment. Cancer Lett. 600:2171562024. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wan L, Zhang H, Liu J, He Q, Zhao J, Pan
C, Zheng K and Tang Y: Lactylation and human disease. Expert Rev
Mol Med. 27:e102025. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang Y, Luo N, Gong Z, Zhou W, Ku Y and
Chen Y: Lactate and lysine lactylation of histone regulate
transcription in cancer. Heliyon. 10:e384262024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhu Y, Liu W, Luo Z, Xiao F and Sun B: New
insights into the roles of lactylation in cancer. Front Pharmacol.
15:14126722024. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang W, Shan G, Bi G, Hu Z, Yi Y, Zeng D,
Lin Z and Zhan C: Lactylation and regulated cell death. Biochim
Biophys Acta Mol Cell Res. 1872:1199272025. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li H, Liu C, Li R, Zhou L, Ran Y, Yang Q,
Huang H, Lu H, Song H, Yang B, et al: AARS1 and AARS2 sense
L-lactate to regulate cGAS as global lysine lactyltransferases.
Nature. 634:1229–1237. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhu R, Ye X, Lu X, Xiao L, Yuan M, Zhao H,
Guo D, Meng Y, Han H, Luo S, et al: ACSS2 acts as a lactyl-CoA
synthetase and couples KAT2A to function as a lactyltransferase for
histone lactylation and tumor immune evasion. Cell Metab.
37:361–376 e7. 2025. View Article : Google Scholar
|
|
46
|
Ju J, Zhang H, Lin M, Yan Z, An L, Cao Z,
Geng D, Yue J, Tang Y, Tian L, et al: The alanyl-tRNA synthetase
AARS1 moonlights as a lactyltransferase to promote YAP signaling in
gastric cancer. J Clin Invest. 134:e1745872024. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tsusaka T, Najar MA, Sharma I,
Marcinkiewicz MM, Crispim CVDS, Snyder NW, Burslem GM and Goldberg
EL: Class I histone deacetylases catalyze lysine lactylation.
bioRxiv [Preprint] 2025.02.25.640220. 2025.
|
|
48
|
Urbanska K and Orzechowski A:
Unappreciated Role of LDHA and LDHB to control apoptosis and
autophagy in tumor cells. Int J Mol Sci. 20:20852019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tsukihara S, Akiyama Y, Shimada S, Hatano
M, Igarashi Y, Taniai T, Tanji Y, Kodera K, Yasukawa K, Umeura K,
et al: Delactylase effects of SIRT1 on a positive feedback loop
involving the H19-glycolysis-histone lactylation in gastric cancer.
Oncogene. 44:724–738. 2025. View Article : Google Scholar
|
|
50
|
Zou Y, Cao M, Tai M, Zhou H, Tao L, Wu S,
Yang K, Zhang Y, Ge Y, Wang H, et al: A feedback loop driven by
H4K12 lactylation and HDAC3 in macrophages regulates
lactate-induced collagen synthesis in fibroblasts via the TGF-beta
signaling. Adv Sci (Weinh). 12:e24114082025. View Article : Google Scholar
|
|
51
|
He X, Li Y, Li J, Li Y, Chen S, Yan X, Xie
Z, Du J, Chen G, Song J and Mei Q: HDAC2-Mediated METTL3
delactylation promotes DNA damage repair and chemotherapy
resistance in triple-negative breast cancer. Adv Sci (Weinh).
12:e24131212025. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xu Y, Meng W, Dai Y, Xu L, Ding N, Zhang J
and Zhuang X: Anaerobic metabolism promotes breast cancer survival
via Histone-3 Lysine-18 lactylation mediating PPARD axis. Cell
Death Discov. 11:542025. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang S, Huang T, Wu Q, Yuan H, Wu X, Yuan
F, Duan T, Taori S, Zhao Y, Snyder NW, et al: Lactate reprograms
glioblastoma immunity through CBX3-regulated histone lactylation. J
Clin Invest. 134:e1768512024. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Fan M, Yang K, Wang X, Chen L, Gill PS, Ha
T, Liu L, Lewis NH, Williams DL and Li C: Lactate promotes
endothelial-to-mesenchymal transition via Snail1 lactylation after
myocardial infarction. Sci Adv. 9:eadc94652023. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhang T, Chen L, Kueth G, Shao E, Wang X,
Ha T, Williams DL, Li C, Fan M and Yang K: Lactate's impact on
immune cells in sepsis: Unraveling the complex interplay. Front
Immunol. 15:14834002024. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhang X, Liang C, Wu C, Wan S and Xu L,
Wang S, Wang J, Huang X and Xu L: A rising star involved in tumour
immunity: Lactylation. J Cell Mol Med. 28:e701462024. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Shi P, Ma Y and Zhang S: Non-histone
lactylation: Unveiling its functional significance. Front Cell Dev
Biol. 13:15356112025. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Li W, Zhou C, Yu L, Hou Z, Liu H, Kong L,
Xu Y, He J, Lan J, Ou Q, et al: Tumor-derived lactate promotes
resistance to bevacizumab treatment by facilitating autophagy
enhancer protein RUBCNL expression through histone H3 lysine 18
lactylation (H3K18la) in colorectal cancer. Autophagy. 20:114–130.
2024. View Article : Google Scholar :
|
|
59
|
Li F, Zhang H, Huang Y, Li D, Zheng Z, Xie
K, Cao C, Wang Q, Zhao X, Huang Z, et al: Single-cell transcriptome
analysis reveals the association between histone lactylation and
cisplatin resistance in bladder cancer. Drug Resist Updat.
73:1010592024. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Yu Y, Huang X, Liang C and Zhang P:
Evodiamine impairs HIF1A histone lactylation to inhibit
Sema3A-mediated angiogenesis and PD-L1 by inducing ferroptosis in
prostate cancer. Eur J Pharmacol. 957:1760072023. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhou J, Xu W, Wu Y, Wang M, Zhang N, Wang
L, Feng Y, Zhang T, Wang L and Mao A: GPR37 promotes colorectal
cancer liver metastases by enhancing the glycolysis and histone
lactylation via Hippo pathway. Oncogene. 42:3319–30. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chen B, Deng Y, Hong Y, Fan L, Zhai X, Hu
H, Yin S, Chen Q, Xie X, Ren X, et al: Metabolic recoding of
NSUN2-mediated m(5)C modification promotes the progression of
colorectal cancer via the NSUN2/YBX1/m(5)C-ENO1 positive feedback
loop. Adv Sci (Weinh). 11:e23098402024. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Hou J, Guo M, Li Y and Liao Y: Lactylated
histone H3K18 as a potential biomarker for the diagnosis and
prediction of the severity of pancreatic cancer. Clinics (Sao
Paulo). 80:1005442024. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Li F, Si W, Xia L, Yin D, Wei T, Tao M,
Cui X, Yang J, Hong T and Wei R: Positive feedback regulation
between glycolysis and histone lactylation drives oncogenesis in
pancreatic ductal adenocarcinoma. Mol Cancer. 23:902024. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Yu Y, Li Y, Zhou L, Cheng X and Gong Z:
Hepatic stellate cells promote hepatocellular carcinoma development
by regulating histone lactylation: Novel insights from single-cell
RNA sequencing and spatial transcriptomics analyses. Cancer Lett.
604:2172432024. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Ding CH, Yan FZ, Xu BN, Qian H, Hong XL,
Liu SQ, Luo YY, Wu SH, Cai LY, Zhang X, et al: PRMT3 drives
PD-L1-mediated immune escape through activating PDHK1-regulated
glycolysis in hepatocellular carcinoma. Cell Death Dis. 16:1582025.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Chao J, Chen GD, Huang ST, Gu H, Liu YY,
Luo Y, Lin Z, Chen ZZ, Li X, Zhang B, et al: High histone H3K18
lactylation level is correlated with poor prognosis in epithelial
ovarian cancer. Neoplasma. 71:319–332. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Huang Y, Che X, Wang PW and Qu X: p53/MDM2
signaling pathway in aging, senescence and tumorigenesis. Semin
Cancer Biol. 101:44–57. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zong Z, Xie F, Wang S, Wu X, Zhang Z, Yang
B and Zhou F: Alanyl-tRNA synthetase, AARS1, is a lactate sensor
and lactyltransferase that lactylates p53 and contributes to
tumorigenesis. Cell. 187:2375–2392 e33. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Zhao R, Yi Y, Liu H, Xu J, Chen S, Wu D,
Wang L and Li F: RHOF promotes Snail1 lactylation by enhancing
PKM2-mediated glycolysis to induce pancreatic cancer cell
endothelial-mesenchymal transition. Cancer Metab. 12:322024.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Sun K, Zhang X, Shi J, Huang J, Wang S, Li
X, Lin H, Zhao D, Ye M, Zhang S, et al: Elevated protein
lactylation promotes immunosuppressive microenvironment and
therapeutic resistance in pancreatic ductal adenocarcinoma. J Clin
Invest. 135:e1870242025. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Meng Q, Sun H, Zhang Y, Yang X, Hao S, Liu
B, Zhou H, Xu ZX and Wang Y: Lactylation stabilizes DCBLD1
activating the pentose phosphate pathway to promote cervical cancer
progression. J Exp Clin Cancer Res. 43:362024. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Yang Z, Yan C, Ma J, Peng P, Ren X, Cai S,
Shen X, Wu Y, Zhang S, Wang X, et al: Lactylome analysis suggests
lactylation-dependent mechanisms of metabolic adaptation in
hepatocellular carcinoma. Nat Metab. 5:61–79. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Cheng Z, Huang H, Li M and Chen Y:
Proteomic analysis identifies PFKP lactylation in SW480 colon
cancer cells. iScience. 27:1086452023. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Batsios G, Taglang C, Udutha S, Gillespie
AM, Robinson SP, Phoenix T, Mueller S, Venneti S, Koschmann C and
Viswanath P: Lactylation fuels nucleotide biosynthesis and
facilitates deuterium metabolic imaging of tumor proliferation in
H3K27M-mutant gliomas. bioRxiv. Jan 3–2025.Epub ahead of print.
|
|
76
|
Dong F, Yin H and Zheng Z:
Hypoxia-inducible factor-1alpha regulates BNIP3-dependent mitophagy
and mediates metabolic reprogramming through histone lysine
lactylation modification to affect glioma proliferation and
invasion. J Biochem Mol Toxicol. 39:e700692025. View Article : Google Scholar
|
|
77
|
Zhu J and Zhang Y: Dexmedetomidine
inhibits the migration, invasion, and glycolysis of glioblastoma
cells by lactylation of c-myc. Neurol Res. 46:1105–1112. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Trejo-Solis C, Castillo-Rodriguez RA,
Serrano-Garcia N, Silva-Adaya D, Vargas-Cruz S, Chavez-Cortez EG,
Gallardo-Perez JC, Zavala-Vega S, Cruz-Salgado A and
Magana-Maldonado R: Metabolic roles of HIF1, c-Myc, and p53 in
glioma cells. Metabolites. 14:2492024. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Zhang M, Zhao Y, Liu X, Ruan X, Wang P,
Liu L, Wang D, Dong W, Yang C and Xue Y: Pseudogene MAPK6P4-encoded
functional peptide promotes glioblastoma vasculogenic mimicry
development. Commun Biol. 6:10592023. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Uba AI: Computer-aided design of VEGFR-2
inhibitors as anticancer agents: A review. J Mol Recognit.
38:e31042025. View Article : Google Scholar
|
|
81
|
Mehta K, Hegde M, Girisa S, Vishwa R,
Alqahtani MS, Abbas M, Shakibaei M, Sethi G and Kunnumakkara AB:
Targeting RTKs/nRTKs as promising therapeutic strategies for the
treatment of triple-negative breast cancer: Evidence from clinical
trials. Mil Med Res. 11:762024.PubMed/NCBI
|
|
82
|
Batlle E and Clevers H: Cancer stem cells
revisited. Nat Med. 23:1124–1134. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Agosti E, Zeppieri M, Ghidoni M, Ius T,
Tel A, Fontanella MM and Panciani PP: Role of glioma stem cells in
promoting tumor chemo- and radioresistance: A systematic review of
potential targeted treatments. World J Stem Cells. 16:604–614.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Friess D, Brauer S, Poysti A, Choudhury C
and Harris L: Tools to study neural and glioma stem cell
quiescence. Trends Neurosci. 47:736–748. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ramar V, Guo S, Hudson B and Liu M:
Progress in glioma stem cell research. Cancers (Basel). 16:1022023.
View Article : Google Scholar
|
|
86
|
Agosti E, Antonietti S, Ius T, Fontanella
MM, Zeppieri M and Panciani PP: Glioma stem cells as promoter of
glioma progression: A systematic review of molecular pathways and
targeted therapies. Int J Mol Sci. 25:79792024. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Tang J, Amin MA and Campian JL:
Glioblastoma stem cells at the nexus of tumor heterogeneity, immune
evasion, and therapeutic resistance. Cells. 14:5622025. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Li G, Wang D, Zhai Y, Pan C, Zhang J, Wang
C, Huang R, Yu M, Li Y, Liu X, et al: Glycometabolic
reprogramming-induced XRCC1 lactylation confers therapeutic
resistance in ALDH1A3-overexpressing glioblastoma. Cell Metab.
36:1696–1710 e10. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Zhou Z, Yin X, Sun H, Lu J, Li Y, Fan Y,
Lv P, Han M, Wu J, Li S, et al: PTBP1 lactylation promotes glioma
stem cell maintenance through PFKFB4-Driven glycolysis. Cancer Res.
85:739–757. 2025. View Article : Google Scholar
|
|
90
|
Li L, Li Z, Meng X, Wang X, Song D, Liu Y,
Xu T, Qin J, Sun N, Tian K, et al: Histone lactylation-derived
LINC01127 promotes the self-renewal of glioblastoma stem cells via
the cis-regulating the MAP4K4 to activate JNK pathway. Cancer Lett.
579:2164672023. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Russo M, Chen M, Mariella E, Peng H,
Rehman SK, Sancho E, Sogari A, Toh TS, Balaban NQ, Batlle E, et al:
Cancer drug-tolerant persister cells: From biological questions to
clinical opportunities. Nat Rev Cancer. 24:694–717. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Kuczynski EA, Sargent DJ, Grothey A and
Kerbel RS: Drug rechallenge and treatment beyond
progression-implications for drug resistance. Nat Rev Clin Oncol.
10:571–587. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Liu J, Yang F, Hu J and Zhang X:
Nanoparticles for efficient drug delivery and drug resistance in
glioma: New perspectives. CNS Neurosci Ther. 30:e147152024.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Huo X, Li H, Xing Y, Liu W, Chen P, Du F,
Song L, Yu Z, Cao X and Tian J: Two decades of progress in glioma
methylation research: The rise of temozolomide resistance and
immunotherapy insights. Front Neurosci. 18:14407562024. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Chen T, Ma W, Wang X, Ye Q, Hou X, Wang Y,
Jiang C, Meng X, Sun Y and Cai J: Insights of immune cell
heterogeneity, tumor-initiated subtype transformation, drug
resistance, treatment and detecting technologies in glioma
microenvironment. J Adv Res. 72:527–554. 2025. View Article : Google Scholar :
|
|
97
|
Davidson CL, Vengoji R, Jain M, Batra SK
and Shonka N: Biological, diagnostic and therapeutic implications
of exosomes in glioma. Cancer Lett. 582:2165922024. View Article : Google Scholar :
|
|
98
|
Brown R, Curry E, Magnani L,
Wilhelm-Benartzi CS and Borley J: Poised epigenetic states and
acquired drug resistance in cancer. Nat Rev Cancer. 14:747–753.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Shibue T and Weinberg RA: EMT, CSCs, and
drug resistance: The mechanistic link and clinical implications.
Nat Rev Clin Oncol. 14:611–629. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Munoz JL, Walker ND, Scotto KW and
Rameshwar P: Temozolomide competes for P-glycoprotein and
contributes to chemoresistance in glioblastoma cells. Cancer Lett.
367:69–75. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Zhang X, Tan Y, Li T, Tan D, Fu B, Yang M,
Chen Y, Cao M, Xuan C, Du Q, et al: Intercellular adhesion
molecule-1 suppresses TMZ chemosensitivity in acquired
TMZ-resistant gliomas by increasing assembly of ABCB1 on the
membrane. Drug Resist Updat. 76:1011122024. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Oldrini B, Vaquero-Siguero N, Mu Q, Kroon
P, Zhang Y, Galan-Ganga M, Bao Z, Wang Z, Liu H, Sa JK, et al: MGMT
genomic rearrangements contribute to chemotherapy resistance in
gliomas. Nat Commun. 11:38832020. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Agarwal S, Al-Keilani MS, Alqudah MA,
Sibenaller ZA, Ryken TC and Assem M: Tumor derived mutations of
protein tyrosine phosphatase receptor type K affect its function
and alter sensitivity to chemotherapeutics in glioma. PLoS One.
8:e628522013. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Su IC, Su YK, Chuang HY, Yadav VK,
Setiawan SA, Fong IH, Yeh CT, Huang HC and Lin CM:
Ubiquitin-specific protease 6 n-terminal-like protein (USP6NL) and
the epidermal growth factor receptor (EGFR) signaling axis
regulates ubiquitin-mediated DNA repair and temozolomide-resistance
in glioblastoma. Biomedicines. 10:15312022. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Li Y, Wang T, Wan Q, Wang Q, Chen Z, Gao
Y, Ye Y, Lin J, Zhao B, Wang H, et al: TRAF4 maintains
deubiquitination of caveolin-1 to drive glioblastoma stemness and
temozolomide resistance. Cancer Res. 82:3573–3587. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Gao XY, Zang J, Zheng MH, Zhang YF, Yue
KY, Cao XL, Cao Y, Li XX, Han H, Jiang XF and Liang L: Temozolomide
treatment induces HMGB1 to promote the formation of glioma stem
cells via the TLR2/NEAT1/Wnt pathway in glioblastoma. Front Cell
Dev Biol. 9:6208832021. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Pu J, Yuan K, Tao J, Qin Y, Li Y, Fu J, Li
Z, Zhou H, Tang Z, Li L, et al: Glioblastoma multiforme: An updated
overview of temozolomide resistance mechanisms and strategies to
overcome resistance. Discov Oncol. 16:7312025. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Yu D, Zhong Q, Wang Y, Yin C, Bai M, Zhu
J, Chen J, Li H and Hong W: Lactylation: The metabolic accomplice
shaping cancer's response to radiotherapy and immunotherapy. Ageing
Res Rev. 104:1026702025. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Fan M, Liu JS, Wei XL, Nie Y and Liu HL:
Histone lactylation-driven ubiquitin-specific protease 34 promotes
cisplatin resistance in hepatocellular carcinoma. Gastroenterology
Res. 18:23–30. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Zhang K, Guo L, Li X, Hu Y and Luo N:
Cancer-associated fibroblasts promote doxorubicin resistance in
triple-negative breast cancer through enhancing ZFP64 histone
lactylation to regulate ferroptosis. J Transl Med. 23:2472025.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Yue Q, Wang Z, Shen Y, Lan Y, Zhong X, Luo
X, Yang T, Zhang M, Zuo B, Zeng T, et al: Histone H3K9 lactylation
confers temozolomide resistance in glioblastoma via LUC7L2-Mediated
MLH1 intron retention. Adv Sci (Weinh). 11:e23092902024. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Liu R, Ren X, Park YE, Feng H, Sheng X,
Song X, AminiTabrizi R, Shah H, Li L, Zhang Y, et al: Nuclear
GTPSCS functions as a lactyl-CoA synthetase to promote histone
lactylation and gliomagenesis. Cell Metab. 37:377–394 e9. 2025.
View Article : Google Scholar
|
|
113
|
Cai J, Song L, Zhang F, Wu S, Zhu G, Zhang
P, Chen S, Du J, Wang B, Cai Y, et al: Targeting SRSF10 might
inhibit M2 macrophage polarization and potentiate anti-PD-1 therapy
in hepatocellular carcinoma. Cancer Commun (Lond). 44:1231–1260.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Hu X, Huang Z and Li L: LDHB mediates
histone lactylation to activate PD-L1 and promote ovarian cancer
immune escape. Cancer Invest. 43:70–79. 2025. View Article : Google Scholar
|
|
115
|
Huang C, Xue L, Lin X, Shen Y and Wang X:
Histone lactylation-driven GPD2 mediates M2 macrophage polarization
to promote malignant transformation of cervical cancer progression.
DNA Cell Biol. 43:605–618. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Ma Z, Yang J, Jia W, Li L, Li Y, Hu J, Luo
W, Li R, Ye D and Lan P: Histone lactylation-driven B7-H3
expression promotes tumor immune evasion. Theranostics.
15:2338–2359. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Deng X, Huang Y, Zhang J, Chen Y, Jiang F,
Zhang Z, Li T, Hou L, Tan W and Li F: Histone lactylation regulates
PRKN-Mediated mitophagy to promote M2 macrophage polarization in
bladder cancer. Int Immunopharmacol. 148:1141192025. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Li Z, Liang P, Chen Z, Chen Z, Jin T, He
F, Chen X and Yang K: CAF-secreted LOX promotes PD-L1 expression
via histone lactylation and regulates tumor EMT through TGFβ/IGF1
signaling in gastric cancer. Cell Signal. 124:1114622024.
View Article : Google Scholar
|
|
119
|
Wang W, Wang H, Wang Q, Yu X and Ouyang L:
Lactate-induced protein lactylation in cancer: Functions,
biomarkers and immunotherapy strategies. Front Immunol.
15:15130472025. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Hao ZN, Tan XP, Zhang Q, Li J, Xia R and
Ma Z: Lactate and lactylation: Dual regulators of T-cell-mediated
tumor immunity and immunotherapy. Biomolecules. 14:16462024.
View Article : Google Scholar :
|
|
121
|
Raychaudhuri D, Singh P, Chakraborty B,
Hennessey M, Tannir AJ, Byregowda S, Natarajan SM, Trujillo-Ocampo
A, Im JS and Goswami S: Histone lactylation drives CD8(+) T cell
metabolism and function. Nat Immunol. 25:2140–2151. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Zhang C, Zhou L, Zhang M, Du Y, Li C, Ren
H and Zheng L: H3K18 lactylation potentiates immune escape of
non-small cell lung cancer. Cancer Res. 84:3589–3601. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
123
|
De Leo A, Ugolini A, Yu X, Scirocchi F,
Scocozza D, Peixoto B, Pace A, D'Angelo L, Liu JKC, Etame AB, et
al: Glucose-driven histone lactylation promotes the
immunosuppressive activity of monocyte-derived macrophages in
glioblastoma. Immunity. 57:1105–1123 e8. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Li M, Sun P, Tu B, Deng G, Li D and He W:
Hypoxia conduces the glioma progression by inducing M2 macrophage
polarization via elevating TNFSF9 level in a
histone-lactylation-dependent manner. Am J Physiol Cell Physiol.
327:C487–C504. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Mulvey A, Trueb L, Coukos G and Arber C:
Novel strategies to manage CAR-T cell toxicity. Nat Rev Drug
Discov. 24:379–397. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Diorio C, Teachey DT and Grupp SA:
Allogeneic chimeric antigen receptor cell therapies for cancer:
Progress made and remaining roadblocks. Nat Rev Clin Oncol.
22:10–27. 2025. View Article : Google Scholar
|
|
127
|
Tang L, Huang ZP, Mei H and Hu Y: Insights
gained from single-cell analysis of chimeric antigen receptor
T-cell immunotherapy in cancer. Mil Med Res. 10:522023.PubMed/NCBI
|
|
128
|
Uslu U and June CH: Beyond the blood:
Expanding CAR T cell therapy to solid tumors. Nat Biotechnol.
43:506–515. 2025. View Article : Google Scholar
|
|
129
|
Sun T, Liu B, Li Y, Wu J, Cao Y, Yang S,
Tan H, Cai L, Zhang S, Qi X, et al: Oxamate enhances the efficacy
of CAR-T therapy against glioblastoma via suppressing
ectonucleotidases and CCR8 lactylation. J Exp Clin Cancer Res.
42:2532023. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Silva A, Antunes B, Batista A,
Pinto-Ribeiro F, Baltazar F and Afonso J: In vivo anticancer
activity of AZD3965: A systematic review. Molecules. 27:1812021.
View Article : Google Scholar
|
|
131
|
Xian ZY, Liu JM, Chen QK, Chen HZ, Ye CJ,
Xue J, Yang HQ, Li JL, Liu XF and Kuang SJ: Inhibition of LDHA
suppresses tumor progression in prostate cancer. Tumour Biol.
36:8093–8100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Le A, Cooper CR, Gouw AM, Dinavahi R,
Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL and Dang
CV: Inhibition of lactate dehydrogenase A induces oxidative stress
and inhibits tumor progression. Proc Natl Acad Sci USA.
107:2037–2042. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Rajeshkumar NV, Dutta P, Yabuuchi S, de
Wilde RF, Martinez GV, Le A, Kamphorst JJ, Rabinowitz JD, Jain SK,
Hidalgo M, et al: Therapeutic targeting of the warburg effect in
pancreatic cancer relies on an absence of p53 function. Cancer Res.
75:3355–3364. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Mohammad GH, Vassileva V, Acedo P, Olde
Damink SWM, Malago M, Dhar DK and Pereira SP: Targeting pyruvate
kinase M2 and lactate dehydrogenase a is an effective combination
strategy for the treatment of pancreatic cancer. Cancers (Basel).
11:13722019. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Hao J, Graham P, Chang L, Ni J, Wasinger
V, Beretov J, Deng J, Duan W, Bucci J, Malouf D, et al: Proteomic
identification of the lactate dehydrogenase A in a radioresistant
prostate cancer xenograft mouse model for improving radiotherapy.
Oncotarget. 7:74269–74285. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Gao S, Tu DN, Li H, Jiang JX, Cao X, You
JB and Zhou XQ: Pharmacological or genetic inhibition of LDHA
reverses tumor progression of pediatric osteosarcoma. Biomed
Pharmacother. 81:388–393. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Rellinger EJ, Craig BT, Alvarez AL, Dusek
HL, Kim KW, Qiao J and Chung DH: FX11 inhibits aerobic glycolysis
and growth of neuroblastoma cells. Surgery. 161:747–752. 2017.
View Article : Google Scholar
|
|
138
|
He Y, Chen X, Yu Y, Li J, Hu Q, Xue C,
Chen J, Shen S, Luo Y, Ren F, et al: LDHA is a direct target of
miR-30d-5p and contributes to aggressive progression of gallbladder
carcinoma. Mol Carcinog. 57:772–783. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Hou X, Shi X, Zhang W, Li D, Hu L, Yang J,
Zhao J, Wei S, Wei X, Ruan X, et al: LDHA induces EMT gene
transcription and regulates autophagy to promote the metastasis and
tumorigenesis of papillary thyroid carcinoma. Cell Death Dis.
12:3472021. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Jiang J, Roman J, Xu HN and Li LZ: An
observation on enhanced extracellular acidification and lactate
production induced by inhibition of lactate dehydrogenase A. Adv
Exp Med Biol. 1269:163–167. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Polanski R, Hodgkinson CL, Fusi A, Nonaka
D, Priest L, Kelly P, Trapani F, Bishop PW, White A, Critchlow SE,
et al: Activity of the monocarboxylate transporter 1 inhibitor
AZD3965 in small cell lung cancer. Clin Cancer Res. 20:926–937.
2014. View Article : Google Scholar :
|
|
142
|
Bola BM, Chadwick AL, Michopoulos F,
Blount KG, Telfer BA, Williams KJ, Smith PD, Critchlow SE and
Stratford IJ: Inhibition of monocarboxylate transporter-1 (MCT1) by
AZD3965 enhances radiosensitivity by reducing lactate transport.
Mol Cancer Ther. 13:2805–2816. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Huang CY, Hsu LH, Chen CY, Chang GC, Chang
HW, Hung YM, Liu KJ and Kao SH: Inhibition of alternative cancer
cell metabolism of EGFR mutated non-small cell lung cancer serves
as a potential therapeutic strategy. Cancers (Basel). 12:1812020.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Beloueche-Babari M, Wantuch S, Casals
Galobart T, Koniordou M, Parkes HG, Arunan V, Chung YL, Eykyn TR,
Smith PD and Leach MO: MCT1 INHIBITOR AZD3965 increases
mitochondrial metabolism, facilitating combination therapy and
noninvasive magnetic resonance spectroscopy. Cancer Res.
77:5913–5924. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Beloueche-Babari M, Casals Galobart T,
Delgado-Goni T, Wantuch S, Parkes HG, Tandy D, Harker JA and Leach
MO: Monocarboxylate transporter 1 blockade with AZD3965 inhibits
lipid biosynthesis and increases tumour immune cell infiltration.
Br J Cancer. 122:895–903. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Benyahia Z, Blackman MCNM, Hamelin L,
Zampieri LX, Capeloa T, Bedin ML, Vazeille T, Schakman O and
Sonveaux P: In vitro and in vivo characterization of MCT1 inhibitor
AZD3965 confirms preclinical safety compatible with breast cancer
treatment. Cancers (Basel). 13:5692021. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Silva A, Felix A, Cerqueira M, Goncalves
CS, Sampaio-Marques B, Longatto-Filho A, Baltazar F and Afonso J:
Effects of lactate transport inhibition by AZD3965 in
muscle-invasive urothelial bladder cancer. Pharmaceutics.
15:26882023. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Puri S and Juvale K: Monocarboxylate
transporter 1 and 4 inhibitors as potential therapeutics for
treating solid tumours: A review with structure-activity
relationship insights. Eur J Med Chem. 199:1123932020. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Kong SC, Nohr-Nielsen A, Zeeberg K,
Reshkin SJ, Hoffmann EK, Novak I and Pedersen SF: Monocarboxylate
transporters MCT1 and MCT4 regulate migration and invasion of
pancreatic ductal adenocarcinoma cells. Pancreas. 45:1036–1047.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Tung WH, Hsieh HL, Lee IT and Yang CM:
Enterovirus 71 modulates a COX-2/PGE2/cAMP-dependent viral
replication in human neuroblastoma cells: Role of the
c-Src/EGFR/p42/p44 MAPK/CREB signaling pathway. J Cell Biochem.
112:559–570. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
He H, Lai Y, Hao Y, Liu Y, Zhang Z, Liu X,
Guo C, Zhang M, Zhou H, Wang N, et al: Selective p300 inhibitor
C646 inhibited HPV E6-E7 genes, altered glucose metabolism and
induced apoptosis in cervical cancer cells. Eur J Pharmacol.
812:206–215. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Ji C, Xu W, Ding H, Chen Z, Shi C, Han J,
Yu L, Qiao N, Zhang Y, Cao X, et al: The p300 inhibitor A-485
exerts antitumor activity in growth hormone pituitary adenoma. J
Clin Endocrinol Metab. 107:e2291–e2300. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Zhang F, Tang X, Fan S, Liu X, Sun J, Ju
C, Liang Y, Liu R, Zhou R, Yu B, et al: Targeting the p300/NONO
axis sensitizes melanoma cells to BRAF inhibitors. Oncogene.
40:4137–4150. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Gao XN, Lin J, Ning QY, Gao L, Yao YS,
Zhou JH, Li YH, Wang LL and Yu L: A histone acetyltransferase p300
inhibitor C646 induces cell cycle arrest and apoptosis selectively
in AML1-ETO-positive AML cells. PLoS One. 8:e554812013. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Waddell A, Grbic N, Leibowitz K, Wyant WA,
Choudhury S, Park K, Collard M, Cole PA and Alani RM: p300 KAT
regulates SOX10 stability and function in human melanoma. Cancer
Res Commun. 4:1894–1907. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Mladek AC, Yan H, Tian S, Decker PA,
Burgenske DM, Bakken K, Hu Z, He L, Connors MA, Carlson BL, et al:
RBBP4-p300 axis modulates expression of genes essential for cell
survival and is a potential target for therapy in glioblastoma.
Neuro Oncol. 24:1261–1272. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Jin Z, Yun L and Cheng P: Tanshinone I
reprograms glycolysis metabolism to regulate histone H3 lysine 18
lactylation (H3K18la) and inhibits cancer cell growth in ovarian
cancer. Int J Biol Macromol. 291:1390722025. View Article : Google Scholar
|
|
158
|
Zhang C, Zhou W, Xu H, Xu J, Li J, Liu X,
Lu X, Dai J, Jiang Y, Wang W, et al: Cancer-associated fibroblasts
promote EGFR-TKI resistance via the CTHRC1/glycolysis/H3K18la
positive feedback loop. Oncogene. 44:1400–1414. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Sun X, He L, Liu H, Thorne RF, Zeng T, Liu
L, Zhang B, He M, Huang Y, Li M, et al: The diapause-like
colorectal cancer cells induced by SMC4 attenuation are
characterized by low proliferation and chemotherapy insensitivity.
Cell Metab. 35:1563–1579 e8. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Wu Q, Li X, Long M, Xie X and Liu Q:
Integrated analysis of histone lysine lactylation (Kla)-specific
genes suggests that NR6A1, OSBP2 and UNC119B are novel therapeutic
targets for hepatocellular carcinoma. Sci Rep. 13:186422023.
View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Chen H, Li Y, Li H, Chen X, Fu H, Mao D,
Chen W, Lan L, Wang C, Hu K, et al: NBS1 lactylation is required
for efficient DNA repair and chemotherapy resistance. Nature.
631:663–669. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Huang G, Chen S, He J, Li H, Ma Z, Lubamba
GP, Wang L, Guo Z and Li C: Histone lysine lactylation
(Kla)-induced BCAM promotes OSCC progression and Cis-platinum
resistance. Oral Dis. 31:1116–1132. 2025. View Article : Google Scholar
|
|
163
|
Zheng C, Tan H, Niu G, Huang X, Lu J, Chen
S, Li H, Zhu J, Zhou Z, Xu M, et al: ACAT1-Mediated ME2 acetylation
drives chemoresistance in ovarian cancer by linking glutaminolysis
to lactate production. Adv Sci (Weinh). 12:e24164672025. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Pienkowski T, Kowalczyk T, Cysewski D,
Kretowski A and Ciborowski M: Glioma and post-translational
modifications: A complex relationship. Biochim Biophys Acta Rev
Cancer. 1878:1890092023. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Han M, He W, Zhu W and Guo L: The role of
protein lactylation in brain health and disease: Current advances
and future directions. Cell Death Discov. 11:2132025. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Wu X, Zhang X, Tang S and Wang Y: The
important role of the histone acetyltransferases p300/CBP in cancer
and the promising anticancer effects of p300/CBP inhibitors. Cell
Biol Toxicol. 41:322025. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Chen Q, Yang B, Liu X, Zhang XD, Zhang L
and Liu T: Histone acetyltransferases CBP/p300 in tumorigenesis and
CBP/p300 inhibitors as promising novel anticancer agents.
Theranostics. 12:4935–4948. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Liu B, Lin Y, Darwanto A, Song X, Xu G and
Zhang K: Identification and characterization of propionylation at
histone H3 lysine 23 in mammalian cells. J Biol Chem.
284:32288–32295. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Chen Y, Sprung R, Tang Y, Ball H, Sangras
B, Kim SC, Falck JR, Peng J, Gu W and Zhao Y: Lysine propionylation
and butyrylation are novel post-translational modifications in
histones. Mol Cell Proteomics. 6:812–819. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Bhattacharya A, Chatterjee S, Bhaduri U,
Singh AK, Vasudevan M, Sashidhara KV, Guha R, Nazir A, Rath SK,
Natesh N and Kundu TK: Butyrylation meets adipogenesis-probed by a
p300-catalyzed acylation-specific small molecule inhibitor:
Implication in anti-obesity therapy. J Med Chem. 65:12273–12291.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Jiang C, He X, Chen X, Huang J, Liu Y,
Zhang J, Chen H, Sui X, Lv X, Zhao X, et al: Lactate accumulation
drives hepatocellular carcinoma metastasis through facilitating
tumor-derived exosome biogenesis by Rab7A lactylation. Cancer Lett.
627:2176362025. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Deng J, Li Y, Yin L, Liu S, Li Y, Liao W,
Mu L, Luo X and Qin J: Histone lactylation enhances GCLC expression
and thus promotes chemoresistance of colorectal cancer stem cells
through inhibiting ferroptosis. Cell Death Dis. 16:1932025.
View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Dai J, Lu X, Zhang C, Qu T, Li W, Su J,
Guo R, Yin D, Wu P, Han L and Zhang E: NNMT promotes acquired
EGFR-TKI resistance by forming EGR1 and lactate-mediated double
positive feedback loops in non-small cell lung cancer. Mol Cancer.
24:792025. View Article : Google Scholar : PubMed/NCBI
|
